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Abstract 
Background: To date, there are no effective therapeutic targeting agents for triple-negative breast cancer (TNBC), 
and PD-L1 has presented potential as an effective marker of immunotherapeutic agents. The aim of this study was to 
evaluate the expression of PD-L1 by three different immunohistochemical antibodies in TNBC.
Methods: Interpretation of all three PD-L1 antibodies showed good concordance among three readers (kappa value 
>0.610) in both cancer cells and immune cells. Using a tissue microarray (TMA) constructed from 218 cases of TNBC, 
we performed immunohistochemical staining using three of the most popular commercially used PD-L1 monoclonal 
antibodies (clones 28-8, E1L3N and SP142) in cancer cells and immune cells.
Results: Using various cut-off values of previous studies (1, 5, 10 and 50 %), the expression rates in cancer cells were: 
PD-L1 (E1L3N) (14.7, 14.7, 11.0, 2.3 %), PD-L1 (28-8) (13.3, 12.4, 10.1, 1.8 %), and PD-L1 (SP142) (11.5, 11.0, 6.9, 0.5 %), 
respectively. At the 5 % cut-off value, the discordance rate among the three antibodies was 6.0–10.6 % and was high-
est between PD-L1 (SP142) and the other two antibodies. The expression rates in immune cells were PD-L1 (E1L3N) 
(37.6 %), PD-L1 (28-8) (36.7 %), and PD-L1 (SP142) (19.3 %), and the discordance rate among the three antibodies 
ranged from 13.8 to 24.8 % and was also highest between PD-L1 (SP142) and the other two antibodies. Among stro-
mal histologic types, higher PD-L1 expression in cancer cells and immune cells was measured in inflammatory-type 
(p < 0.05). The absence of PD-L1 (28-8) staining in immune cells was associated with shorter disease free survival (DFS) 
and overall survival (OS) (p = 0.043, and p = 0.021) in univariate analyses, and with shorter OS in multivariate Cox 
analysis (hazard ratio: 5.429, 95 % CI 1.214–24.28, p = 0.027).
Conclusions: PD-L1 detection in cancer cells and immune cells varied by antibody clone. The greatest amount of 
staining occurred with PD-L1 (E1L3N), followed by PD-L1 (28-8) and PD-L1 (SP142). The concordance rate among 
monoclonal PD-L1 antibodies was higher between PD-L1 (28-8) and PD-L1 (E1L3N). To determine the gold standard 
antibody and the most appropriate cut-off value, further study of the clinical trial group treated with PD-L1 inhibitor is 
necessary.
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Background
Breast cancer is a heterogeneous disease that has several 
clinical, histological, and genetic forms. There have been 
many attempts to categorize this heterogeneous disease, 
and now molecular classification into five groups (lumi-
nal A, luminal B, HER-2, normal breast-like, and basal-
like) can be accomplished by gene-expression profiling 
[1, 2].
Among these molecular subtypes, basal-like breast 
cancer has a more aggressive clinical course than other 
subtypes and is commonly known as triple-negative 
breast cancer (TNBC), which is defined clinically as lack-
ing estrogen receptor (ER) and progesterone receptor 
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(PR) and human epidermal growth factor receptor 2 
(HER2). TNBC accounts for 10–17 % of all breast cancers 
[3–8]. Highly heterogeneous and known to have several 
molecular subtypes, TNBC is difficult to treat because it 
does not respond to hormonal or targeted therapy such 
as Herceptin, except chemotherapy [9–11].
Programmed death 1 (PD-1) is a check point molecule 
in immune reactions and can be expressed in various 
immune cells [12]. PD-L1, a ligand of PD-1, is expressed 
in cancer cells and the binding of PD-L1 with PD-1 helps 
cancer cells avoid antitumor immune responses [13, 14]. 
PD-L1 expression has been reported at rates of 20–70 % 
in lung cancer [13, 15–18], urinary bladder cancer [19], 
malignant melanoma [20], and ovarian cancer [21]. 
PD-L1 was expressed in not only tumor cells but immune 
cells in previous studies of breast cancer [22–24], and 
lung cancer [25]. In addition, its expression in immune 
cells demonstrated clinical implication [23]. Therefore, 
the evaluation of PD-L1 should be performed in both 
cancer cell and immune cells.
Target therapy for PD-L1 in PD-L1-expressing can-
cers represents a possible treatment for inducing anti-
tumor immune responses. PD-L1-targeted therapy has 
been investigated in preclinical and clinical trials in many 
tumors [15–17, 19, 26–28] and anti-PD-L1 antibodies 
such as BMS-936,559 [29] and MPDL3280A [16, 19] have 
been developed. Knowledge of the expression of PD-L1 
in cancer cells plays an important role in tailored ther-
apy planning, and is easily evaluated using immunohis-
tochemistry (IHC) with a monoclonal PD-L1 antibody 
in formalin-fixed and paraffin-embedded (FFPE) speci-
mens. Multiple monoclonal PD-L1 antibodies such clone 
28-8 [30], clone 22C3 [31], clone SP142 [16, 19], and 
clone E1L3N [32, 33] have been commercially developed.
The aim of this study was to evaluate the expression of 
PD-L1 using different immunohistochemical antibodies 
in TNBC and associated clinical implications.
Methods
Patient selection
We analyzed 218 patients with TNBC who underwent 
surgery at Severance Hospital between January 2000 and 
December 2006. This study was approved by the Institu-
tional Review Board of Severance Hospital. All patients 
were diagnosed as having invasive ductal carcinoma, not 
otherwise specified (NOS) by pathologists. We defined 
TNBC as when IHC for ER, PR, and HER-2 and FISH for 
HER-2 were all negative.
ER and PR immunohistochemistry signal were consid-
ered positive when more than 1 % of invasive tumor cells 
were expressed [34]. HER-2 staining was scored according 
to the American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) guideline using 
the following categories: 0, no immunostaining; 1+, weak 
incomplete membranous staining in any proportion of 
tumor cells; 2+, complete membranous staining, either 
non uniform or weak in at least 10 % of tumor cells; and 
3+, uniform intense membranous staining in >30  % of 
tumor cells [35]. Cases with 0 to 1+ were regarded as neg-
ative and case with 3+ was considered as positive. Cases 
with HER-2 2+ were investigated with FISH (Vysis path-
vision HER-2 kit) for HER-2 gene status. As proposed by 
the ASCO/CAP guideline, an absolute HER-2 gene copy 
number lower than four or HER-2 gene/chromosome 17 
copy number ratio (HER-2/Chr17 ratio) of less than 1.8 
was considered HER-2 negative; an absolute HER-2 copy 
number between 4 and 6 or HER-2/Chr17 ratio between 
1.8 and 2.2 was considered HER-2 equivocal; and an abso-
lute HER2 copy number greater than 6 or HER-2/Chr17 
ratio higher than 2.2 was considered HER-2 positive.
Formalin-fixed and paraffin-embedded tissue speci-
mens from 218 cases of primary breast cancer were 
included. All archival hematoxylin and eosin (H&E)-
stained slides for each case were reviewed by one pathol-
ogists (Koo JS). The histological grade was accessed 
using Nottingham grading system [36]. According to 
the microscopic cancer stoma findings, TNBC was cat-
egorized as follows [37]: desmoplastic type, with cellular 
fibroblast/myofibroblast proliferation as the main stro-
mal content; sclerotic type, which has a small cell com-
ponent and fibrotic collagenous component as its main 
stromal content; or inflammatory type, with stroma 
mainly composed of inflammatory cells such as lympho-
cytes. Tumor staging was based on the 8th American 
Joint Committee on Cancer (AJCC) criteria. Disease-free 
survival (DFS) time was measured from the date of the 
first curative surgery to the date of the first locoregional 
or systemic relapse, or death without any type of relapse. 
Overall survival (OS) time was calculated from the date 
of the first curative operation to the date of the last fol-
low-up or death from any cause. Histologic parameters 
were evaluated from the H&E-stained slides. Clinical 
parameters evaluated in each tumor included patient age 
at initial diagnosis, lymph node status, local recurrence, 
systemic recurrence, and patient’s survival.
Tissue microarray
On H&E-stained slides of tumors, a representative area 
was selected and a corresponding spot was marked on 
the surface of the paraffin block. Using a punch machine, 
the selected area was punched out and a 3-mm tissue 
core was placed into a 6 × 5 recipient block. More than 
two tissue cores were extracted to minimize extraction 
bias. Each tissue core was assigned with a unique tissue 
microarray location number that was linked to a database 
containing other clinicopathologic data.
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Immunohistochemistry (IHC)
The antibodies and dilution used for IHC are shown in 
Additional file  1: Table S1. All immunohistochemistry 
was performed with formalin-fixed, paraffin-embedded 
tissue sections using an automatic immunohistochem-
istry staining device (Benchmark XT, Ventana Medical 
System, Tucson, AZ, USA). Briefly, 5-µm-thick formal-
dehyde fixed paraffin-embedded tissue sections were 
transferred onto adhesive slides and dried at 62  °C for 
30  min. Standard heat epitope retrieval was performed 
for 30  min in ethylene diamine tetraacetic acid, pH 8.0, 
in the autostainer. The samples were then incubated with 
primary antibodies. After incubation with primary anti-
bodies, The sections were subsequently incubated with 
biotinylated anti-mouse immunoglobulins, peroxidase-
labeled streptavidin (LSAB kit, DakoCytomation), and 
3,30-diaminobenzidine. Negative control samples were 
processed without the primary antibody. Slides were 
counterstained with Harris hematoxylin. Positive control 
tissue was used as per the manufacturer’s recommenda-
tion (placenta and tonsil). Slides were counterstained 
with Harris hematoxylin. Optimal primary antibody 
incubation times and concentrations were determined 
by serial dilution for each immunohistochemical assay 
using a tissue block fixed and embedded exactly as for the 
experiments.
Interpretation of immunohistochemical staining
We evaluated the expression of immunohistochemical 
markers in cancer cells and peri-tumoral immune cells by 
light microscopy. Expression in cancer cells was analyzed 
by various cut-off values (1, 5, 10 and 50 %) and expres-
sion in immune cells was analyzed as follows: negative, 
no immunostaining; low-positive, stained immune cells 
≤30/high power field (HPF); and high-positive, stained 
immune cells >30/HPF.
Interpretation of immunohistochemical staining was 
performed independently by three researchers (SWY, 
LYK, KJS). We investigated the proportion of expres-
sion (%) in cancer cells according to the above criteria, 
counted the number of expressed immune cells. Each 
of three pathologists analyzed the samples and reached 
a conclusion, which were then analyzed to determine 
inter-reader concordance. The final results were deter-
mined through discussion and multi-view microscopy 
in the cases that showed discrepancy among the three 
pathologists.
Statistical analysis
Data were analyzed using SPSS for Windows, Version 
12.0 (SPSS Inc., Chicago, IL, USA). For determination 
of statistical significance, Student’s t and Fisher’s exact 
tests were used for continuous and categorical variables, 
respectively. The inter-reader concordance rate and con-
cordance rate among PD-L1 antibodies were analyzed 
using the Kappa-Cohen method. Statistical significance 
was when p  <  0.05. Kaplan–Meier survival curves and 
log-rank statistics were employed to evaluate time to 
tumor recurrence and overall survival. Multivariate 
regression analysis was performed using Cox propor-
tional hazards model.
Results
Basal characteristics of TNBC
Among the 218 TNBC patients, a desmoplastic type was 
observed in 138 cases (63.3  %), inflammatory type in 
63 cases (28.9 %), and sclerotic type in 17 cases (7.8 %). 
There was no difference in clinicopathologic factors 
according to stromal type (Additional file 1: Table S2).
Inter‑reader reproducibility for monoclonal PD‑L1 
antibodies
The kappa values of all three PD-L1 antibodies were 
>0.610 in both cancer cells and immune cells. In cancer 
cells, the concordance rate was highest when using a 1 % 
cut-off value, while the lowest concordance rate was seen 
at the 10 % cut-off value (Table 1).
PD‑L1 monoclonal antibody staining in TNBC cells 
and immune cells
Among the different PD-L1 monoclonal antibodies, 
PD-L1 (E1L3N) showed the highest expression rate in 
cancer cells (14.7, 14.7, 11.0, 2.3  %) and immune cells 
(37.6  %) and PD-L1 (SP142) showed the lowest expres-
sion rate in cancer cells (11.5, 11.0, 6.9, 0.5  %) and 
immune cells (19.3  %) for all cut-off values (1, 5, 10, 
and 50  %) (Table  2; Fig.  1). The kappa value between 
PD-L1 (28-8) and PD-L1 (E1L3N) was higher than those 
between PD-L1 (28-8) and PD-L1 (SP142) and between 
PD-L1 (SP142) and PD-L1 (E1L3N) in both cancer 
cells and immune cells. Therefore, the concordance 
rate among monoclonal PD-L1 antibodies was higher 
between PD-L1 (28-8) and PD-L1 (E1L3N) (Table 3).
At the 5 % cut-off value, the discordance rate between 
PD-L1 (28-8) and PD-L1 (E1L3N) was 6 % (13 cases) and 
was higher in PD-L1 (28-8)-negative/PD-L1 (E1L3N)-
positive (9 cases) than PD-L1 (28-8)-positive/PD-L1 
(E1L3N)-negative (4 cases) cells. The discordance rate 
between PD-L1 (28-8) and PD-L1 (SP142) was 10.6 % (23 
cases) and was higher in PD-L1 (28-8)-positive/PD-L1 
(SP142)-negative (13 cases) than PD-L1 (28-8)-negative/
PD-L1 (SP142)-positive (10 cases) cells. Likewise, dis-
cordance was higher in PD-L1 (E1L3N)-positive/PD-L1 
(SP142)-negative (15 cases) than PD-L1 (E1L3N)-nega-
tive/PD-L1 (SP142)-positive (7 cases) cells (Additional 
file 1: Table S3).
Page 4 of 12Sun et al. J Transl Med  (2016) 14:173 
In immune cells, PD-L1 (E1L3N) had the highest and 
PD-L1 (SP 142) had the lowest total positive expres-
sion rate. The low-positive rate was higher with PD-L1 
(28-8) than PD-L1 (E1L3N); however, the high-positive 
rate was higher with PD-L1 (E1L3N) than PD-L1 (28-
8). In the analysis for expression concordance among 
the three antibodies in immune cells, the discordance 
rate between PD-L1 (28-8) and PD-L1 (E1L3N) was 
13.8 % (30 cases), with 14 PD-L1 (28-8)-positive/PD-L1 
(E1L3N)-negative cases and 16 PD-L1 (28-8)-nega-
tive/PD-L1 (E1L3N)-positive cases. The discordance 
rate between PD-L1 (28-8) and PD-L1 (SP142) was 
24.8 % (54 cases), with 46 PD-L1 (28-8)-positive/PD-L1 
(SP142)-negative cases and 8 PD-L1 (28-8)-negative/
PD-L1 (SP142)-positive cases. Finally, the discordance 
rate between PD-L1 (E1L3N) and PD-L1 (SP142) was 
22.0  % (48 cases), with 44 PD-L1 (E1L3N)-positive/
PD-L1 (SP142)-negative cases and 4 PD-L1 (E1L3N)-
negative/PD-L1 (SP142)-positive cases (Additional file 1: 
Table S4).
Correlation of PD‑L1 expression between cancer cells 
and immune cells
The concordance rate between cancer cells and immune 
cells was higher for PD-L1 (28-8) (p < 0.001). For PD-L1 
(SP142), the concordance rate was higher for posi-
tive staining in cancer cells and in negative staining in 
immune cells (p < 0.001, Table 4).
Correlation between PD‑L1 expression 
and clinicopathologic factors
Correlation in cancer cells was analyzed using a 5 % cut-
off value, as in most previous studies. Among the stro-
mal histologic types, inflammatory-type cancer cells and 
immune cells had the highest PD-L1 expression (p < 0.05, 
Fig.  2). Lymph node metastasis correlated with PD-L1 
(28-8) negativity in cancer cells (p = 0.002), while higher 
Ki-67 LI correlated with PD-L1 (28-8) positivity and 
PD-L1 (E1L3N) positivity in immune cells (p = 0.010 and 
p = 0.001, respectively) (Fig. 3).
Impact of expression of PD‑L1 on patient prognosis 
in TNBC
In univariate analysis, PD-L1 (28-8) negativity in 
immune cells was associated with shorter disease-free 
survival (DFS) and overall survival (OS) (p = 0.043, and 
p = 0.021, Table 6; Fig. 4). In multivariate Cox analysis, 
factors related to shorter DFS included higher T stage 
(hazard ratio: 10.21, 95  % CI 1.306–79.90, p  =  0.027) 
and lymph node metastasis (hazard ratio: 3.918, 95 % CI 
1.254–12.24, p = 0.019), while factors related to shorter 
OS were higher T stage (hazard ratio: 6.317, 95  % CI 
1.413–28.23, p = 0.016), lymph node metastasis (hazard 
ratio: 3.564, 95 % CI 1.304–9.740, p = 0.013), and PD-L1 
(28-8) negativity in immune cells (hazard ratio: 5.112, 
95 % CI 1.110–23.54, p = 0.036, Table 7).  
Discussion
This study sought to evaluate the immunohistochemical 
expression of PD-L1 using several monoclonal antibodies 
in TNBC. We performed IHC under the same conditions 
with different antibody clones and found differences in 
PD-L1 expression in both tumor cells and immune cells 
(Table 7).
Table 1 Kappa value for inter-reader reproducibility of PD-L1 monoclonal antibodies
Reader PD‑L1 (28‑8) PD‑L1 (E1L3N) PD‑L1 (SP142)
Tumor cell Immune  
cell
Tumor cell Immune  
cell
Tumor cell Immune 
cell
1 % 5 % 10 % 50 % 1 % 5 % 10 % 50 % 1 % 5 % 10 % 50 %
#1 to #2 1.000 0.913 0.770 0.838 0.903 1.000 0.943 0.876 0.887 0.914 1.000 0.871 0.889 1.000 0.928
#1 to #3 1.000 0.958 0.923 0.838 0.894 1.000 0.981 0.820 0.887 0.888 1.000 0.976 0.924 1.000 0.858
#2 to #3 1.000 0.913 0.794 0.628 0.798 1.000 0.923 0.670 1.000 0.870 0.977 0.842 0.803 1.000 0.788
Table 2 Expression of  PD-L1 monoclonal antibodies in   
TNBC
Parameters PD‑L1 (28‑8) PD‑L1 (E1L3N) PD‑L1 (SP142)
Cancer cell compartment
 1 % cut-off value
  Negative 189 (86.7) 186 (85.3) 193 (88.5)
  Positive 29 (13.3) 32 (14.7) 25 (11.5)
 5 % cut-off value
  Negative 191 (87.6) 186 (85.3) 194 (89.0)
  Positive 27 (12.4) 32 (14.7) 24 (11.0)
 10 % cut-off value
  Negative 196 (89.9) 194 (89.0) 203 (93.1)
  Positive 22 (10.1) 24 (11.0) 15 (6.9)
50 % cut-off value
  Negative 214 (98.2) 213 (97.7) 217 (99.5)
  Positive 4 (1.8) 5 (2.3) 1 (0.5)
Immune cell compartment
  Negative 138 (63.3) 136 (62.4) 176 (80.7)
  Low positive 59 (27.1) 55 (25.2) 40 (18.3)
  High positive 21 (9.6) 27 (12.4) 2 (0.9)
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Fig. 1 Staining with PD-L1 monoclonal antibodies in TNBC. PD-L1 expression in cancer cells was similarly positive for PD-L1 (clone 28-8) and PD-L1 
(clone E1L3N) antibodies, but low for PD-L1 (clone SP142). Both PD-L1 (clone 28-8) and PD-L1 (clone E1L3N) stained positive in many immune cells, 
while PD-L1 (clone SP142) was mostly negative in this cell type. Placenta and tonsil tissue were used as the positive control
Table 3 Kappa value for inter-PD-L1 antibodies concordance
Antibody Tumor cell Immune cell
1 % cut‑off 5 % cut‑off 10 % cut‑off 50 % cut‑off
PD-L1 (28-8) to PD-L1 (E1L3N) 0.752 0.745 0.660 0.887 0.607
PD-L1 (28-8) to PD-L1 (SP142) 0.535 0.490 0.558 0.396 0.309
PD-L1 (SP142) to PD-L1 (E1L3N) 0.537 0.551 0.580 0.328 0.305
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The high concordance rate among the three readers 
in the interpretation of PD-L1 yielded acceptable inter-
reader reproducibility with a kappa value >0.610 in both 
cancer cells and immune cells. Especially in cancer cells, 
the concordance rate was highest at a 1  % cut-off value 
and lowest at a 10 % cut-off value. This is likely because 
the reader tends to interpret as positive in 1  % cut-off 
even in slight expression and increase concordance rate, 
and tends to have more likely subjective interpreta-
tion in 10 % cut-off value. However, improvement in the 
response rate from 35 % at a 1 % cut-off value to 44 % at 
a 5 % cut-off value was seen in a nivolumab phase I study 
targeting malignant melanoma, indicating that the higher 
5  % cut-off value was more reasonable [38]. Therefore, 
further response-based studies of TNBC are necessary.
Variation in PD-L1 expression rates previously 
observed in a study of various cancers has been attrib-
uted to differences in cut-off values, antibodies, and study 
populations [39, 40], and this phenomenon is also com-
monly seen with other antibodies [41]. In lung cancer 
characterized with PD-L1 expression, expression rates 
varied from 24 to 60 % using the same 5 % cut-off value 
[15, 16, 42], and from 21 to 95 % according to different 
cut-off values of 1, 10 and 50 % [13, 17, 18, 43].
PD-L1 expression in TNBC was present at 19 % (clone 
5H1 with a 5 % cut-off) [44] and 64–80 % (clone E1L3N, 
with a 1 % cut-off) [45] in previous studies. In our study, 
the expression rate was 11.5–14.7  % with a 1  % cut-off 
value and 11.0–14.7 % with a 5 % cut-off value, which was 
similar to the previous report of 19 %. We presume that 
differences in expression rate are due primarily to differ-
ent characteristics of the PD-L1 antibody clones, because 
all samples were stained using the same immunohisto-
chemical conditions.
PD-L1 showed membranous expression in this study, 
in agreement with one previous study in TNBC [44], but 
the other TNBC study reported both cytoplasmic and 
membranous expression of PD-L1 [45]. PD-L1 expres-
sion has been reported in the cell membrane [17, 26–28] 
or membrane and cytoplasm [13, 16, 18] in other can-
cers. We performed IHC using an automatic IHC stain-
ing device, but the previous research in TNBC that 
evaluated cytoplasm expression had no clear description 
of staining, making it difficult to compare our findings 
directly with previous data [45]. We found expression of 
PD-L1 in 19.3–37.6  % of cancer cells and immune cells, 
depending on the antibody clone. Although our expres-
sion rate was different than a previous study with 93  % 
immune cell expression in TNBC, it was in concordance 
with the previous report in terms of positive immune 
cell expression [45]. PD-L1 expression in immune cells 
has been reported in other cancers [16, 19, 25, 28]. There 
are differences between oncogene-driven PD-L1 expres-
sion and inflammation-driven PD-L1 expression. While 
oncogene-driven PD-L1 expression is constitutive and dif-
fuse, inflammation-driven PD-L1 expression is limited to 
sites of IFNγ-mediated immunologic attack [46]. In addi-
tion, inflammation-driven PD-L1 expression is related to 
immune infiltrates, while oncogene-driven PD-L1 expres-
sion is not [28, 47]. Thus, further study to know which 
expression between two expressions is more related to the 
expression of PD-L1 on immune cell in TNBC.
In this study, the concordance rate between PD-L1 (28-
8) and PD-L1 (E1L3N) was high in both cancer cells and 
immune cells while PD-L1 (SP142) showed low concord-
ance rates with the other two antibodies. Previous studies 
reported poor concordance (kappa value: 0.124–0.340) 
between PD-L1 (E1L3N) and PD-L1 (SP142) in lung 
cancer [48], but a high concordance rate between PD-L1 
(E1L3N) and PD-L1 (SP142) (more than 85 %) in malig-
nant melanoma [49]. Therefore, concordance seems to 
vary according to cancer type; further study on this topic 
is needed.
PD-L1 positivity in immune cells (28-8 clone) was an 
independent prognostic factor in our study, in contrast to 
previous studies showing good prognosis [50–53] or poor 
prognosis [54, 55] with PD-L1 expression in cancer cells. 
Since the prognostic and predictive significance of PD-L1 
expression in immune cells such as macrophages and lym-
phocytes was not associated with tumor-related PD-L1 
expression [16], further study of the biologic implications 
of PD-L1 in immune cells during TNBC is needed.
Table 4 Correlation of  expression of  PD-L1 between  can-
cer cell and immune cell
PD‑L1 (28‑8) in cancer cell p value
Negative Positive
PD-L1 (28-8) in immune cell <0.001
 Negative 130 (68.1) 8 (29.6)
 Positive 61 (31.9) 19 (70.4)
PD‑L1 (E1L3N) in cancer  
cell
p value
Negative Positive
PD-L1 (E1L3N) in immune cell 0.117
 Negative 120 (64.5) 16 (50.0)
 Positive 66 (35.5) 16 (50.0)
PD‑L1 (SP142) in cancer  
cell
p value
Negative Positive
PD-L1 (SP142) in immune cell <0.001
 Negative 163 (84.0) 13 (54.2)
 Positive 31 (16.0) 11 (45.8)
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Fig. 2 Staining with PD-L1 monoclonal antibodies according to stromal histologic type. Staining of cancer cells and surrounding immune cells 
using different three antibodies was higher in inflammatory type cells (Table 5)
Fig. 3 Correlation of expression of PD-L1 and clinicopathologic factors in TNBC
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In breast cancer, tumor infiltrating lymphocytes (TILs) 
have been linked with good prognosis [56], as have stro-
mal TIL [57]. Therefore, tumor immunity may relate to 
prognosis in TNBC. PD-L1 expression was significantly 
higher in inflammatory type cancer cells and immune 
cells with all tested antibodies. Therefore, we assume that 
Table 5 PD-L1 expression according to the stromal types in triple negative breast cancer
T tumor cell, I immune cell
Parameters Total
N = 218 (%)
Stromal type p value
Desmoplastic
n = 138 (%)
Inflammatory
n = 63 (%)
Sclerotic
n = 17 (%)
PD-L1 (28-8) (T) 0.005
 Negative 191 (87.6) 127 (92.0) 48 (76.2) 16 (94.1)
 Positive 27 (12.4) 11 (8.0) 15 (23.8) 1 (5.9)
PD-L1 (E1L3N) (T) <0.001
 Negative 186 (85.3) 126 (91.3) 44 (69.8) 16 (94.1)
 Positive 32 (14.7) 12 (8.7) 19 (30.2) 1 (5.9)
PD-L1 (SP142) (T) 0.001
 Negative 194 (89.0) 130 (94.2) 48 (76.2) 16 (94.1)
 Positive 24 (11.0) 8 (5.8) 15 (23.8) 1 (5.9)
PD-L1 (28-8) (I) <0.001
 Negative 138 (63.3) 100 (72.5) 25 (39.7) 13 (76.5)
 Positive 80 (36.7) 38 (27.5) 38 (60.3) 4 (23.5)
PD-L1 (E1L3N) (I) <0.001
 Negative 136 (62.4) 103 (74.6) 20 (31.7) 13 (76.5)
 Positive 82 (37.6) 35 (25.4) 43 (68.3) 4 (23.5)
PD-L1 (SP142) (I) <0.001
 Negative 176 (80.7) 121 (87.7) 40 (63.5) 15 (88.2)
 Positive 42 (19.3) 17 (12.3) 23 (36.5) 2 (11.8)
Table 6 Impact of expression of PD-L1 on disease-free and overall survival tested by log-rank analysis
Italics represents p < 0.05
T tumor cell, I immune cell
Parameters Number of patients / 
recurrence/death
Disease‑free survival Overall survival
Mean survival  
(95 % CI) months
p value Mean survival  
(95 % CI) months
p value
PD-L1 (28-8) (T) N/A 0.967
 Negative 191/16/17 N/A 91 (87–95)
 Positive 27/0/2 N/A 59 (54–64)
PD-L1 (E1L3N) (T) N/A 0.647
 Negative 186/16/17 N/A 90 (86–95)
 Positive 32/0/2 N/A 91 (84–98)
PD-L1 (28-8) (I) 0.043 0.021
 Negative 138/14/17 89 (84–93) 87 (82–92)
 Positive 80/2/2 97 (94–100) 97 (94–100)
PD-L1 (E1L3N) (I) 0.761 0.255
 Negative 136/11/15 91 (87–95) 88 (84–93)
 Positive 82/5/4 94 (89–98) 95 (90–99)
PD-L1 (SP142) (I) 0.191 0.387
 Negative 176/15/17 90 (86–94) 89 (85–93)
 Positive 42/1/2 97 (93–101) 95 (89–100)
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PD-L1 expression in stromal immune cells is related to 
prognosis, and further research is needed to better eluci-
date this relationship.
Clinical trials targeting PD-L1 are underway [17, 58–60] 
and good responses have been reported [61, 62]. In TNBC, 
which has no effective therapy, PD-L1-targeting agents may 
play an important role and strong biomarkers that can pre-
dict treatment response are needed. Accordingly, staining 
of PD-L1 monoclonal antibodies may act as a biomarker for 
PD-L1-targeting agents, but clinical trials evaluating TNBC 
response to PD-L1-targeting agents using monoclonal anti-
body staining will be needed to validate this strategy.
The limitation of this study was the potential difference 
in results between TMA and the whole cancer tissue sec-
tion. Breast cancer also shows intracancer heterogeneity, 
like other types of cancer, and the expression of PD-L1 
may cause differences between TMA and the whole 
cancer tissue section. PD-L1 expression in lung cancer 
showed a high discordance rate between TMA sam-
ples and whole tissue sections [48]. In a previous study, 
the results of immunohistochemical staining of ER in 
breast cancer were different in 5.5 % between TMA and 
the whole cancer tissue section. Furthermore, when the 
number of cores was greater than one, this difference 
Fig. 4 Disease-free survival and overall survival according to PD-L1 (28-8) staining in immune cells
Table 7 Multivariate analysis of triple negative breast cancer survival
Italics represents p < 0.05
I immune cell
Included parameters Disease‑free survival Overall survival
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
Histologic grade 0.560 0.204
 I/II versus III 0.725 0.246–2.136 0.537 0.206–1.402
T stage 0.027 0.016
 T1 versus T2/T3 10.21 1.306–79.90 6.317 1.413–28.23
Lymph node metastasis 0.019 0.013
 No versus Yes 3.918 1.254–12.24 3.564 1.304–9.740
Ki-67 LI 0.327 0.711
 ≤14 versus >14 0.581 0.197–1.719 1.209 0.443–3.298
Stromal type 0.988 0.699
 Desmoplastic/sclerotic versus inflammatory 0.990 0.266–19.15 1.287 0.359–4.613
PD-L1 (28-8) (I) 0.081 0.036
 Negative versus positive 4.019 0.843–19.15 5.112 1.110–23.54
Page 10 of 12Sun et al. J Transl Med  (2016) 14:173 
decreased to 1.4  % [63]. In this study, two core extrac-
tions per case were performed to reduce this bias.
Conclusions
In conclusion, staining with PD-L1 (clone 28-8), PD-L1 
(clone E1L3N), and PD-L1 (clone SP142) monoclonal 
antibodies in cancer cells and immune cells varied, with 
the highest staining by PD-L1 (E1L3N) and the lowest by 
PD-L1 (SP142). The concordance rate among monoclo-
nal PD-L1 antibodies was higher between PD-L1 (28-8) 
and PD-L1 (E1L3N). PD-L1 positivity in immune cells 
correlated with a favorable prognosis. To determine the 
gold standard antibody and the most appropriate cut-off 
value, further study of the clinical trial group treated with 
PD-L1 inhibitor is necessary.
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